Adherium named as finalist for OBN Annual Awards 2017
28 Jul 2017
Adherium (ASX : ADR), a global leader in digital health technologies that address sub-optimal medication use in chronic disease, has been selected as a finalist for the OBN Awards 2017. The awards celebrate innovation and achievement across the UK life sciences industry and the winners will be selected by an esteemed panel of judges.
The category Adherium has been shortlisted for is:
Best Implementation of Digital Healthcare – for providing smart personal medication monitoring systems to help patients manage their chronic respiratory conditions
Adherium’s proprietary technology, Smartinhaler™ addresses a global health challenge by improving medication adherence for sufferers of asthma and chronic obstructive pulmonary disease (COPD). The platform comprises a connected sensor device, apps that connect with the device and provide patient reminders, and cloud based software for analysis of patient medication usage data by caregivers. The Smartinhaler™ platform is the most clinically proven solution in the digital health space and has been supplied to >65 clinical trials, with 30 new clinical trials ongoing/underway, and is now being used in over 40 UK NHS hospitals.
Arik Anderson, CEO of Adherium said: “Being shortlisted for this award is a huge honor, and testament to our team and our technology. The Smartinhaler™ platform is built on years of research and has been extensively validated in both UK and mainland European studies. We have partnered with AstraZeneca, to combine our technology with their inhaler medications, to help enable improvements in patient health and reduce the significant costs associated with non-adherence.”
The full details of the nominations can be found at: http://www.obn-awards.com/award-categories/
The awards will be presented at the 9th OBN Annual Awards evening on Thursday 5th October 2017, taking place at the Oxford Town Hall.